retatrutide clinical trials south africa Representation of racialised and ethnically diverse populations in multicentre randomised controlled of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps Retatrutide Phase 3: TRIUMPH Program

The drugs for weight loss are becoming even more accessible with drug makers announcing a daily pill form of the active ingredient semaglutide rather than injecting the drugs on a weekly basis

GLP-1 medications reduce appetite and significantly lower overall calorie intake, which also reduces your intake and absorption of essential vitamins, minerals and protein

This creates the largest affordability gap in obesity medication access

The Triple Agonist Mechanism: Why Retatrutide Is Different To understand why retatrutide produces greater weight loss than any previous medication, you need to understand what makes it mechanistically different

Inflammatory markers may normalize over a few months